The Division of Pharmaceutical Sciences operates with a mission to improve efficacy and reduce toxicity of drug therapy. Fundamental science has always been represented in our research portfolio, with faculty exploring mechanisms of drug transport, drug metabolism, and the genetic basis for interindividual differences in response to drug therapy. We continue to build on our groundbreaking efforts in pharmacogenomics and lead the world in discovery and clinical application. Our faculty are dissecting coding and non-coding regions of the genome to drive improvements in drug therapy, developing more accurate models of pediatric cancers for preclinical evaluation, and elucidating the basis of resistance to anticancer and anti-infective agents. The Division integrates expertise in pharmacokinetics, pharmacodynamics, and pharmacogenomics with state-of-the-art technologies to establish new knowledge and improve patient care.
Our research focus areas
-
Samuel Brady, PhD
-
William E. Evans, PharmD
-
Markos Leggas, PhD
-
Peijun Ma, PhD
-
Mary V. Relling, PharmD
-
P. David Rogers, PharmD, PhD, FCCP
-
Jeffrey M. Rybak, PharmD, PhD
-
Daniel Savic, PhD
-
John D. Schuetz, PhD
-
Clinton F. Stewart, PharmD
-
Jun J. Yang, PhD
-
Liqin Zhu, PhD
Affiliated programs
